Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol.

Article Details

Citation

Copy to clipboard

Marone G, Ambrosio G, Bonaduce D, Genovese A, Triggiani M, Condorelli M

Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol.

Int Arch Allergy Appl Immunol. 1984;74(4):356-61.

PubMed ID

6203844 [ View in PubMed

]

Abstract

Fenoterol, a beta 2-adrenergic agonist recently introduced to treat asthmatic disorders, inhibits antigen-induced histamine release from human basophil leukocytes and lung mast cells in a dose-dependent fashion. The dose-response inhibition curve is paralleled by a fenoterol-induced increase in the cAMP levels of human leukocyte preparations. The relationship between the effect of fenoterol and cAMP level is supported by the finding that the beta 2-adrenergic agonist only inhibits the first stage of antigen-induced histamine release and not the release caused by the Ca2+ ionophore, A23187. Propranolol, a competitive antagonist of beta 2-adrenergic receptor, blocks the inhibition of release and the cAMP accumulation caused by fenoterol. Finally, theophylline, a cAMP phosphodiesterase inhibitor, synergistically potentiates the inhibitory effect of fenoterol on histamine release and the accumulation of cAMP. These data suggest that fenoterol may modulate the in vivo release of the mediators of immediate hypersensitivity reactions via the activation of beta 2-adrenergic receptor linked to adenylate cyclase on human basophils and mast cells.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Fenoterol	Beta-2 adrenergic receptor	Protein	Humans	Yes	Agonist	Details